A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. - Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B 3rd; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA 3rd (Clinical breast cancer, 2020)